Fullwidth Featured
Prediction markets and their opponents are spending more to influence Congress in 2026
Kalshi and groups representing the casino and gaming industry and online sports betting apps, all have boosted their lobbying spending in 2026.
RFK Jr. says cyclospora outbreak is ‘under control’
Health and Human Services Secretary Robert F. Kennedy Jr. on Tuesday said that the ongoing outbreak of cyclosporiasis is “under control.”
The Fed rang the alarm about Anthropic’s Mythos AI model — but had to go months without it
The central bank didn’t have access to Claude Mythos Preview as of mid-July, even as other institutions were racing to patch their vulnerabilities.
Goldman Sachs creates private markets platform as rich investors seek the next SpaceX and Stripe
Goldman Sachs is launching a new alternative investments platform aimed at giving wealthy clients and family offices direct stakes in private companies.
$100M New Jersey deli fraudster James Patten sentenced to 21 months in prison
James Patten was sentenced Tuesday to 21 months in prison in the New Jersey deli case.
Wall Street is selling more rental homes, as buying ban takes effect
The largest landlords are all net sellers year to date, with 3,180 more homes sold than bought since Jan. 1.
IRS chief Frank Bisignano laughs off JPMorgan spying allegations
Bisignano denied allegations The Wall Street Journal reported that he surveilled his colleagues while working at JPMorgan more than a decade ago.
GM announces new gas-powered Cadillac vehicles amid EV pullback
GM CEO Mary Barra said Tuesday the next-generation Cadillacs will include new versions of the CT5 sedan, XT5 midsize SUV and discontinued three-row XT6 SUV.
OpenAI, Anthropic boost lobbying as legacy tech and defense spending slips
The two AI developers spent a combined $3.17 million in the second quarter, up 23% from the first three months of 2026.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo asked the court to permanently stop Lilly from running the “deceptive” ads and require the drugmaker to issue corrective advertising.